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A B S T R A C T
Assessment of molecular signatures of tumors in addition to their anatomy and morphology is desired
for effective diagnostic and therapeutic procedures. Development of in vivo imaging techniques that can
identify and monitor molecular composition of tumors remains an important challenge in pre-clinical
research and medical practice. Here we present a molecular photoacoustic imaging technique that can
visualize the presence and activity of an important cancer biomarker – epidermal growth factor receptor
(EGFR), utilizing the effect of plasmon resonance coupling between molecular targeted gold
nanoparticles. Speciﬁcally, spectral analysis of photoacoustic images revealed profound changes in
the optical absorption of systemically delivered EGFR-targeted gold nanospheres due to their molecular
interactions with tumor cells overexpressing EGFR. In contrast, no changes in optical properties and,
therefore, photoacoustic signal, were observed after systemic delivery of non-targeted gold
nanoparticles to the tumors. The results indicate that multi-wavelength photoacoustic imaging
augmented with molecularly targeted gold nanoparticles has the ability to monitor molecular speciﬁc
interactions between nanoparticles and cell-surface receptors, allowing visualization of the presence
and functional activity of tumor cells. Furthermore, the approach can be used for other cancer cell-
surface receptors such as human epidermal growth factor receptor 2 (HER2). Therefore, ultrasound-
guided molecular photoacoustic imaging can potentially aid in tumor diagnosis, selection of customized
patient-speciﬁc treatment, and monitor the therapeutic progression and outcome in vivo.
 2015 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Molecular imaging techniques capable of good penetration
depth in living tissue remain an important challenge in basic
and clinical science including modern biology and medicine
[1–4]. Optical imaging can provide unprecedented wealth of
molecular speciﬁc information. However, tissue turbidity limitsAbbreviations: AuNPs, gold nanoparticles; EGFR, epidermal growth factor receptor;
PA, photoacoustic.
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4.0/).penetration depth of light in vivo to a few hundred micrometers for
high-resolution imaging modalities such as confocal microscopy,
optical coherence tomography (OCT), or two-photon ﬂuorescence
[5–8]. Approaches based on diffusely scattered light such as diffuse
optical tomography (DOT) can extend this limit to several
centimeters, but they suffer from low resolution and rely on
complex reconstruction algorithms that require a priori knowledge
of tissue optical properties. A unique solution to this problem is the
recently emerging photoacoustic imaging technique that combines
optical excitation and ultrasound detection [9–12]. This imaging
approach relies on ‘‘one-way’’ propagation of diffusive photons
into the tissue where the photoacoustic signal is generated
through thermal interaction of pulsed laser light with photo-
absorbers. Hence the contrast mechanism in photoacoustic
imaging is primarily related to the optical absorption propertiesle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
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Fig. 1. Schematic showing change in optical absorption properties of EGFR-targeted
AuNPs upon interaction with a cancer cell overexpressing EGFR. Activated EGF
receptors undergo dimerization and further aggregation in the plasma membrane,
followed by internalization through endocytosis. The EGFR-targeted AuNPs
associated in this process undergo a progressive color change (i.e., change in
optical absorption) from green to red and near-infrared as depicted in the
absorbance spectra at various stages of AuNPs interaction with the cancer cell.
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the spatial resolution of photoacoustic imaging is determined by
the ability of the ultrasound transducer to resolve the three-
dimensional distribution of photoabsorbers that generate photo-
acoustic transient waves. Photoacoustic imaging can visualize
optical absorption properties of tissue at sufﬁcient depth, and
salient features of photoacoustic imaging are described in several
reviews in recent years [9–15]. Furthermore, a synergistic
integration of photoacoustic imaging with clinically available
ultrasound imaging systems is also possible and is being pursed
[9–12].
Endogenous contrast in photoacoustic imaging is largely
limited to hemoglobin and melanin molecules. In other applica-
tions, detection of lipid and collagen is possible with photoacoustic
imaging [13,16–18]. Detection of other biomarkers or functionality
associated with tumors requires availability of molecular probes or
molecular speciﬁc contrast agents targeted to these biomarkers
[14,15,19,20]. Plasmonic gold and silver nanoparticles are ideally
suited for photoacoustics because of their high absorption cross-
sections [10,11,20]. Molecular speciﬁcity is conferred to these
plasmonic nanoparticles via conjugation to probe molecules such
as antibodies [21,22]. However, the sole addition of a targeting
moiety is often not sufﬁcient for sensitive molecular imaging
because of the background signal generated by the non-speciﬁc
delivery of contrast agents to the imaging site. In cancer imaging,
non-speciﬁc delivery of contrast agents is related to leaky
vasculature of the tumor i.e., contrast agents accumulate in the
tumor site primarily due to the enhanced permeability and
retention (EPR) effect. As done in immunohistological protocols,
extensive blocking and washing steps cannot be applied in vivo to
remove non-speciﬁc binding. Multiple innovative strategies have
been developed to enable highly speciﬁc molecular imaging – for
example, in ﬂuorescence imaging, various activatable probes and
beacons are used to provide signal only in the presence of a
biomarker of interest or detect a change in the signal on a cue from
the tumor micro-environment [23–25]. However, again, most of
these approaches are limited to optical modalities that do not
possess sufﬁcient penetration depth in vivo.
We and other groups have previously showed that targeted
plasmonic nanoparticles by themselves can be used in a similar
way as activatable contrast agents in molecular optical imaging
[10,14,15,19,20,26–28]. The approach is based on the phenomenon
of plasmon resonance coupling between closely spaced noble
metal nanoparticles [26,27,29,30]. The coupling results in strong
optical changes including red spectral shift and broadening of
nanoparticle extinction spectra [21,26,27,29–31]. The formation of
closely spaced assemblies can be mediated by speciﬁc interactions
between targeted gold nanoparticles and a biomolecule of interest
such as a cancer biomarker, e.g. epidermal growth factor receptor
(EGFR) [31]. Confocal reﬂectance and dark-ﬁeld optical imaging of
EGFR positive cancer cells labeled with anti-EGFR antibody
conjugated spherical gold nanoparticles showed a red shift of
more than 100 nm in nanoparticle plasmon resonance frequency
[27,31]. Further studies revealed that the observed optical changes
are associated with EGFR activation and trafﬁcking – key signaling
pathways that determine cell behavior in normal and cancerous
tissue [31]. As activated EGF receptors undergo dimerization and
further aggregation in the plasma membrane, followed by
internalization through endocytosis [31], the EGFR-targeted
AuNPs associated with this process undergo a progressive change
in optical properties (i.e., change in optical absorption) as
schematically depicted in Fig. 1. Therefore, antibody targeted gold
nanoparticles undergo dramatic optical changes upon binding to
activated EGF receptors and endocytosis in live cells. We
previously demonstrated molecular-speciﬁc photoacoustic imag-
ing in three-dimensional cell culture phantoms and ex vivo tissue[21]. This approach is not unique to EGFR molecules and has also
been applied to monitoring actin reorganization, detection of
ﬁbronectin–intergrin complexes, and imaging membrane mor-
phology in live cells [30,31].
Here, we report multi-wavelength photoacoustic imaging of
cancer cells in a xenograft murine tumor model in vivo using the
effect of plasmon resonance coupling of EGFR-targeted gold
nanoparticles. Speciﬁcally, when targeted AuNPs bind to EGFR
molecules, trafﬁcking of the labeled receptors results in receptor-
mediated aggregation of AuNPs inside endosomal compartments
causing plasmon resonance coupling between closely spaced
AuNPs (Fig. 1). This leads to a strong increase in absorption
(thereby increase in photoacoustic signal) in the red spectral
region [26,27,29,31]. These changes in optical properties provide
the unique opportunity for photoacoustic imaging to monitor
molecular speciﬁc interactions between nanoparticles and cell-
surface receptors, allowing visualization of the presence and
functional activity of viable tumor cells.
2. Materials and methods
2.1. Photoacoustic imaging system
The combined ultrasound and photoacoustic imaging system
(Fig. 2a) was based on an ultrasound engine (Winprobe Corpora-
tion, North Palm Beach, FL, USA) interfaced with either a Q-
switched Nd:YAG laser (532 nm wavelength, 5 ns pulses, 20 Hz
pulse repetition frequency) or a tunable OPO laser system (680–
950 nm wavelength, 7 ns pulses, 10 Hz pulse repetition frequency).
The laser ﬂuences were within 10–20 J/cm2 according to the
American National Standards Institute (ANSI) safe exposure level
for human skin. To image the tumor, an integrated imaging probe
consisting of a 7.5 MHz center frequency ultrasound transducer
(14 mm wide, and 128 element linear array) and a bundle of optical
ﬁbers for laser light delivery (Fig. 2b) was used. The axial, lateral,
Fig. 2. (a) The schematic of the combined ultrasound and photoacoustic imaging
system used in this study. (b) Custom designed water-tank with optical window to
allow ultrasound and photoacoustic imaging of subcutaneous tumors in mice. The
optical ﬁbers required for light delivery were attached to the ultrasound transducer
to sequentially obtain ultrasound and photoacoustic images at the same tumor
cross-section.
Fig. 3. The absorbance spectra of the A431 cells incubated for 30 min with
PEGylated AuNPs or EGFR-targeted AuNPs. The inset shows TEM image of
PEGylated AuNPs (20 nm in diameter).
S. Mallidi et al. / Photoacoustics 3 (2015) 26–3428and elevational resolution of the transducer are 250, 300, and
500 mm, respectively.
The integrated probe was attached to a three-dimensional
positioning stage to facilitate volumetric ultrasound and photo-
acoustic imaging by moving the probe in steps of 400 mm in
horizontal direction (orthogonal to the imaging plane). The light
source, ultrasound imaging system and the positioning axes were
interfaced to capture spatially co-registered RF ultrasound and
photoacoustic data as described elsewhere [32]. Ultrasound and
multi-wavelength photoacoustic RF data were acquired at each
position of the integrated probe and stored for off-line processing.
2.2. Multi-wavelength photoacoustic image analysis
The collected RF data is beamformed using delay-and-sum
approach as published previously. The absolute values of the
photoacoustic analytic signals obtained at various wavelengths
were normalized to compensate for the wavelength dependent
laser ﬂuence output. The multi-wavelength photoacoustic images
were analyzed using intraclass correlation to identify regions of
oxygenated/deoxygenated blood and nanoparticles [28]. Intraclass
correlation is a method used in assessing agreement between
different observers or different methods when used on the same
set of subjects. The normalized spectrum of the photoacoustic
signal at a pixel was compared individually to the known spectra of
endocytosed nanoparticles [21] (Fig. 3) and oxygenated/deoxy-
genated hemoglobin [33]. The procedure is repeated for every pixel
in the multi-wavelength photoacoustic image stack, and the
resulting correlation coefﬁcients were used to form an image. To
obtain the spatial distribution of endocytosed nanoparticles,
oxygenated blood, and deoxygenated blood, the correlation maps
were thresholded (correlation coefﬁcient greater than 0.75 were
considered positive) and pseudocolored orange, red and blue for
endocytosed AuNPs, oxygenated hemoglobin, and deoxygenatedhemoglobin, respectively. The distribution map was displayed over
the ultrasound image i.e., ultrasonic image was displayed if the
correlation-based signal was smaller than a user-deﬁned threshold
or vice versa.
2.3. Preparation of bioconjugated AuNPs
Gold nanoparticles (20 nm in diameter) were prepared using
citrate reduction of tetrachloroauric (III) acid (HAuCl4) under reﬂux
(Frens method). TEM image of the nanoparticles is shown in Fig. 3
inset. Anti-EGFR monoclonal antibody (C225, Sigma) was conju-
gated to the AuNPs using procedure described by Kumar et al.
[30]. Brieﬂy, the carbohydrate moiety on the Fc region of the
antibody (Ab) was oxidized to an aldehyde by addition of 100 mM
NaIO4 to a 1 mg/mL Ab solution in HEPES (1:10 by volume). The Ab
was then allowed to react with a hydrazide PEG di-thiol
heterobifunctional linker (Sensopath Technologies, Inc.), where
the hydrazide portion of the linker covalently bonded to the
aldehyde portion of the Ab, yielding an exposed di-thiol moiety
which could react strongly with the AuNPs. The Ab-linker was
centrifuged in a 100 kD MWCO ﬁlter (Amicon) and resuspended in
40 mM HEPES at pH 8 (5 mg/mL). The Ab-linker was mixed with
AuNPs (12 mL, 4  1010 particles/mL) at a 1:1 volume ratio and
reacted on a shaker for 30 min at room temperature. Any
remaining bare gold was capped with mPEG-SH (1.2 mL,
105 M, 5 kD, Creative PEGWorks) and the particles were washed
via centrifugation at 1500 g in the presence of PEG (15 kD, Sigma).
The non-targeted AuNPs were prepared by reacting AuNPs (12 mL,
4  1010 particles/mL) with mPEG-SH (1.2 mL, 105 M, 5 kD,
Creative PEGWorks). The resulting PEGylated particles were also
washed in the presence of PEG via centrifugation at 1500 g. Both
the EGFR-targeted and non-targeted (PEGylated) AuNPs were
sterile ﬁltered before being administered to the nude mice. The
molecular speciﬁcity of the EGFR-targeted AuNPs was also tested
with cells possessing positive expression of EGFR (A431 cells)
using previously published protocols [21]. The absorbance spectra
of the A431 cells incubated 30 min with non-targeted AuNPs or
EGFR-targeted AuNPs are shown in Fig. 3. The cells mixed with
PEGylated AuNPs have an absorbance peak around 520 nm similar
to a suspension of isolated gold nanoparticles. The absorbance of
cells incubated with EGFR-targeted AuNPs has the peak red-shifted
and broadened due to EGFR-mediated aggregation of gold
nanoparticles [21]. These absorbance spectra were used as a
S. Mallidi et al. / Photoacoustics 3 (2015) 26–34 29guideline in multi-wavelength photoacoustic image analysis.
Approximately 250 mL of nanoparticle solution consisting about
500 mg of gold was injected directly into the tumor region using a
27 gauge needle or injected into the mouse blood stream using a
tail vein catheter (MTV01, SAI Infusion Technologies).
2.4. Murine tumor models
The tumors were inoculated in immunodeﬁcient, albino colored
female Nu/Nu mice. The mice were anesthetized with an
intraperitoneal injection of Avertin (0.4–0.75 mg per gram of
body weight). Either human epithelial carcinoma cell line (A431
cell line) or human breast cancer cell line (MDA-MB-435 cell line)
were utilized in our experiments. Approximately 4–5  106 cells
suspended in 300 mL of phosphate buffered saline was injected
subcutaneously in the ﬂank of the mice. The tumors were
inoculated on the lower peripheral region of the mouse to cause
minimal tissue motion due to cardiac and respiratory cycle of the
mouse during the in vivo imaging procedures. The animal facility
was maintained under a 12-hr light/dark cycle at a temperature of
20–22 8C and a relative humidity of 20–50%. The weight of the mice
and the tumor size were monitored until the tumors were
approximately 0.6–1 cm in diameter (approximately 3 weeks post
implantation). All methods used in this study were approved by
the Animal Care and Use Committee at the University of Texas at
Austin. Each experimental group in this study had at least 3 mice.
During the imaging procedures, the mouse was anesthetized
using isoﬂurane gas. Isoﬂurane was chosen due to its less toxic
nature on the mouse’s metabolism. Speciﬁcally a dose of 1%
isoﬂurane mixed with pure oxygen at a 1 L/min ﬂow rate was used.
The body temperature of the animal was maintained at 37 8C using
a heating pad (THM 100, Indus Instruments). The heart rate of the
mouse was monitored every 15 min during the imaging procedure
to ensure well-being. A commercially available ultrasound gel
(Aquasonic Gel, Parker Laboratories) was applied to the tumor
region to establish contact between the mouse skin and ﬂexible
window (polyethylene ﬁlm) at the bottom of a custom-built water
tank (Fig. 2b). The transducer with the ﬁber bundle was placed in
the water tank to facilitate in vivo imaging.Fig. 4. Ultrasound and photoacoustic images of EGFR-positive A431 tumors directly injec
signal (obtained at 720 nm wavelength illumination) from the tumor region is plotted as
the photoacoustic signal was observed when tumors were injected with PEGylated AuN
targeted AuNPs indicating nano-molecular interactions between the nanoparticles and th
represents 5 mm.2.5. Histological analysis details
The tumors were extracted after euthanizing the mice via
approved protocols. The tumors were stored in formalin for 24 h
and transferred to 70% ethanol for storage until tissue processing.
The tumors were placed in parafﬁn cassettes for immunohis-
tochemistry in a similar orientation as the imaging cross-section to
facilitate qualitative comparison of ultrasound and photoacoustic
images with histology images. The hematoxylin and eosin stain
(H&E stain) was performed to identify the tissue structure. The
hematoxylin colors basophilic structures (such as the cell nucleus),
and the eosin dye colors eosinophilic structures (intracellular or
extracellular protein such as cytoplasm) bright pink. Silver staining
procedure [34] was utilized to identify the presence of AuNPs in
the tumor tissue. When AuNP labeled tissue are silver stained, the
produced bimetallic nanoparticles can be easily observed using
bright ﬁeld microscopy even in the presence of standard
histological stains. A counter stain using nuclear fast red was
performed to enhance contrast between the AuNPs and the tissue
when observed under a brightﬁeld microscope.
3. Results and discussion
In the ﬁrst set of mice the molecular-speciﬁc nanoparticles
were injected directly to the tumor region to evaluate if
photoacoustic imaging (Fig. 4) can monitor interactions between
tumor cells and AuNPs. Mice with subcutaneous tumors formed
using EGFR expressing A431 human keratinocytes were injected
with either EGFR-targeted AuNPs or PEGylated AuNPs directly into
the tumors. Ultrasound and multi-wavelength photoacoustic
imaging of the central cross-section of the tumor was performed
before and immediately after intratumoral injection. In addition,
3D images were acquired at 2 h and 4 h after intratumoral injection
of the nanoparticles.
Ultrasound images show mouse skin as a hyperechoic region
within the tumor region demarcated by a white inset in Fig. 4a and
d. The corresponding photoacoustic images (obtained at 720 nm
wavelength illumination, i.e., away from the 520 nm peak
absorption of individual gold nanospheres) of tumors injectedted with either (a–c) PEGylated or (d–f) EGFR-targeted AuNPs. (g) The photoacoustic
 a function of time (n = 3 mice per group). No signiﬁcant (p-value > 0.05) increase in
Ps. However the photoacoustic signal increased over time after injection of EGFR-
e cancer cells resulting in a plasmon resonance coupling of the AuNPs. The scale bar
S. Mallidi et al. / Photoacoustics 3 (2015) 26–3430with either PEGylated AuNPs or EGFR-targeted AuNPs are shown in
Fig. 4c and f, respectively. Clearly the tumor injected with EGFR-
targeted AuNPs show an increase in the photoacoustic signal at
720 nm (Fig. 4f) whereas no increase in the photoacoustic signal
was observed in the tumor injected with PEGylated AuNPs (Fig. 4c).
This change in the photoacoustic signal is due to the molecular
interactions of EGFR-targeted AuNPs with EGFR overexpressing
tumor cells (Fig. 4f). No change in the photoacoustic signal was
observed in the tumor injected with PEGylated AuNPs (i.e., no
increase while background signal remains the same over time).
Given that the non-targeted nanoparticles do not interact with
cancer cells, there is no receptor-mediated endocytosis and,
therefore, no plasmon coupling and no red-shift in the optical
absorption of the PEGylated AuNPs in the tissue was observed.
Quantitative analysis of the temporal changes in the photoacoustic
signals indicate a clear enhancement at 720 nm in the tumor
injected with EGFR-targeted AuNPs (Fig. 4g). The photoacoustic
signal amplitude was normalized with respect to the photo-
acoustic signal obtained at 532 nm irradiation to compensate for
possible differences in the AuNPs concentration in the imaging
planes. Furthermore, the photoacoustic signal from tumor injected
with EGFR-targeted AuNPs increased as a function of time (Fig. 4g)
due to the continuous trafﬁcking of EGFR-targeted AuNPs from the
cell membrane to early endosomes and later to late endosomes/
multivesicular bodies resulting in a time-dependent red shift in
optical properties of AuNPs [31]. In contrast, the tumor injected
with PEGylated AuNPs showed insigniﬁcant temporal change in
the photoacoustic signal from the tumor region. The results
presented in Fig. 4 suggest that the combined ultrasound andFig. 5. In this study three groups of mice were used. The ﬁrst and the second group of mice
as a control, was inoculated using EGFR-negative MDA-MB-435 cells. The ﬁrst and th
administered to the second group. Over time, nanoparticles extravasated into the tumor v
region, no plasmon coupling effect was observed in the tumors from the second and th
aggregation in tumors belonging to the ﬁrst group of mice. The receptor-mediated aggrphotoacoustic imaging has the ability to monitor molecular
interactions of epidermal growth factor receptor (EGFR) with
molecular-speciﬁc AuNPs.
In the next series of experiments we validated our imaging
approach using an intravenous administration of AuNPs in three
groups of mice (Fig. 5). The ﬁrst and the second group had EGFR-
positive A431 tumors. The third group was inoculated with EGFR-
negative breast adenocarcinoma MDA-MB-435 cell line. The ﬁrst
and the third group were injected with EGFR-targeted AuNPs. In
the second group PEGylated AuNPs were administered at the
concentration two times higher than that used in the other two
groups. Ultrasound and multi-wavelength photoacoustic images of
tumor regions were acquired at the same spatial locations before
and up to 4 h after administration of AuNPs. Multi-wavelength
photoacoustic images were analyzed to identify regions containing
endocytosed nanoparticles, oxygenated blood, and deoxygenated
blood [28].
In all animals (Figs. 6 and 7), the tumor region was easily
identiﬁed in ultrasound images. Typically, the subcutaneous tumor
appears as a hyperechoic region (skin, top of the image) with a
hypoechoic area denoting the tumor. In the ﬁrst group of mice with
EGFR-positive tumor and injected with molecular-speciﬁc AuNPs,
photoacoustic images obtained at 720 nm excitation (Fig. 6a)
clearly indicate an increase in the photoacoustic signal over time
after administration of EGFR-targeted AuNPs. Similar to results
shown in Fig. 4, the photoacoustic images in Fig. 6a show an
increase of the photoacoustic signal amplitude over time and,
therefore, indicate both successful delivery of the nanoparticles
and their receptor-mediated interaction with cancer cells. To had xenografts of A431 cells that overexpress EGFR. The third group of mice, serving
e third groups were injected with EGFR-targeted AuNPs. PEGylated AuNPs were
ia the leaky tumor vasculature. Despite signiﬁcant accumulation of AuNPs in tumor
ird group. On the other hand, EGFR-targeted AuNPs underwent receptor-mediated
egation resulted in a strong red-shift in the optical absorption properties of AuNPs.
Fig. 6. (a) Ultrasound images shown in grayscale overlaid with photoacoustic images obtained at 720 nm before and after I.V. administration of EGFR-targeted AuNPs in
mouse with A431 EGFR expressing tumor (Group 1). (b) Multi-wavelength photoacoustic images are pseudo-colored to show oxygenated areas in red, deoxygenated areas in
blue, and molecular speciﬁc interactions between Au NPs and cancer cells in orange. H&E stain (c) and Silver stain (d) of tumor section taken at the imaging cross-section after
injection of AuNPs Dark regions in the silver stained section show the presence of AuNPs. There is a clear time-dependent increase in the photoacoustic signal at 720 nm after
I.V injection of EGFR-targeted AuNPs indicating receptor-mediated aggregation of AuNPs in cellular endosomes. The aggregation leads to plasmon resonance coupling
between AuNPs that results in a red-shift in optical absorption of the nanoparticles. As photoacoustic signal is proportional to optical absorption of the tissue, a time-
dependent increase in photoacoustic signal is observed due to the plasmon resonance coupling effect. 3-D Ultrasound (grayscale) and overlaid photoacoustic images (red
scale) of an EGFR-expressing tumor (e) before and (f) 4 h after administration of EGFR-targeted gold nanoparticles. The bounding box represents a
12 mm  12 mm  13.3 mm ﬁeld of view. A heterogeneous distribution of the PA signal associated with receptor-mediated endocytosis of AuNPs in the tumor is
clearly visible in (f).
Fig. 7. Ultrasound images are shown in grayscale. Multi-wavelength photoacoustic images are pseudo-colored to show oxygenated areas in red, deoxygenated areas in blue,
and aggregated Au NPs in orange. The histology sections of the tumors are taken approximately near the imaging cross-section. Dark regions in silver stained sections show
presence of AuNPs. The data in (a and b) represent the results obtained for Group 3 mice (MDA-MB-435 tumor, EGFR-targeted AuNPs) and in (c and d) from Group 2 mice (A31
tumors, PEGylated AuNPs). Despite signiﬁcant accumulation of AuNPs in the tumors, there were no detectable photoacoustic signals at 720 nm due to lack of interactions
between the AuNPs and the cancer cells.
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Fig. 8. The graphs depicting change in PA signal at 720 nm relative to the photoacoustic signal at 532 nm at 30 min (blue bars), 2 h (red bars), and 4 h (green bars) post I.V
injection of AuNPs. The data are summarized from (a) Group 1 mice (A431 tumors, EGFR-targeted AuNPs), (b) Group 2 mice (A431 tumors, PEGylated AuNPs) and (c) Group
3 mice (MDA-MB-435 tumor, EGFR-targeted AuNPs). Only viable regions in Group 1 mice showed an increase in PA signal at 720 nm that is associated with receptor-mediated
plasmon resonance coupling of AuNPs. The error bars indicate S.E.M.
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hemoglobin) or exogenous (endocytosed nanoparticles) chromo-
phores, spectroscopic photoacoustic imaging was carried out
(Fig. 6b). The images show a heterogeneous distribution of AuNPs
in the tumor region that correlated well with viable tumor regions
identiﬁed in the adjacent H&E stained tissue slices (Fig. 6c). Indeed,
the central tumor regions were necrotic (e.g., area outlined by
white square in Fig. 6c) while the peripheral areas of the tumor
contained viable cells (e.g., area outlined by yellow square in
Fig. 6c). Silver stain of gold nanoparticles in tissue slices showed
that nanoparticles were present within the entire tumor region
(Fig. 6d). However, the observed increase in the photoacoustic
signal was localized only to the viable regions of the tumor. This
result indicates sensitivity of our method toward the presence of
functional EGFR-expressing tumor cells. Fig. 6e and f shows a 3D
ultrasound and spectroscopic photoacoustic images of the tumor
from an animal in the ﬁrst group before and 4 h after intravenous
injection of EGFR-targeted AuNPs respectively. These 3D images
clearly demonstrate that AuNPs did not have a homogeneous
distribution in the tumor. The 3D photoacoustic images visualized
in context of the anatomical structure of tumor provide us with the
functional map of the viable EGFR expressing tumor cells that
interacted with the injected molecular speciﬁc contrast agent. In
this particular tumor, the viable regions are located mostly at the
tumor periphery while the necrotic core or the central region of the
tumor did not have a detectable PA signal. No increase in the
photoacoustic signal at NIR wavelengths was observed in the other
two groups after AuNP administration. Spectroscopic photoacous-
tic images (Fig. 7a and c) do not indicate the presence of
endocytosed nanoparticles despite the accumulation of AuNPs
in the tumor as shown by silver staining of tissue sections (Fig. 7b
and d). The mice in the second group had the EGFR-positive tumor,
and the animals were injected with nonspeciﬁc PEGylated AuNPs.
Consequently, there were no molecular/cellular interactions
between PEGylated nanoparticles and tumor cells, and the 720-
nm photoacoustic images did not show an increase in photo-
acoustic response in spite of injecting double the amount of AuNPs
in the second group. Finally, the third group of mice had tumors
that did not have EGFR expression, and the injected EGFR-targeted
AuNPs just extravasated into the tumor but did not undergo any
nano-molecular interactions with tumor cells. Therefore, there was
no plasmon resonance coupling between the nanoparticles and no
change in the photoacoustic signal at 720 nm. The results
presented in Figs. 6 and 7 clearly indicate molecular speciﬁcity
of EGFR-targeted AuNPs and the ability of photoacoustic imaging
to visualize depth-resolved nano-molecular interactions in vivo.
To further quantify these results, the photoacoustic signals
obtained at 720 nm wavelength illumination in the viable and
necrotic regions of the tumor were compared at various timepoints before and after injection of AuNPs (Fig. 8). In each case, to
compensate for the difference in AuNPs uptake between the
tumors, 720-nm photoacoustic signals were normalized with
photoacoustic signals obtained at 532 nm. Clearly, in the ﬁrst
group (Fig. 8a), the photoacoustic signal in the viable cell region of
the tumors increased over time indicating delivery and receptor-
mediated interaction of targeted nanoparticles with cancer cells.
On the other hand, the necrotic region of the same tumors did not
have an increase in the photoacoustic contrast at 720 nm. In groups
2 and 3 (Fig. 8b and c), the photoacoustic signal did not increase
over time in either the viable or necrotic regions of the tumors (p-
value >0.05).
Plasmonic nanoparticles with different optical absorption
properties can be conjugated to various cancer speciﬁc biomarkers
such as growth factor receptors and integrins [22,35]. The
ultrasound-guided spectroscopic photoacoustic imaging could
be used to image the multiplex labeling and interactions of
nanoparticles with cancer cells in vivo [28]. Identiﬁcation of the
molecular basis of tumor dissemination is driving drug develop-
ment to discover or synthesize inhibitors that block key pathways
in this process. Ultrasound-guided photoacoustic imaging can aid
in understanding the molecular signature of cancers, thus guiding
implementation of speciﬁc therapeutic procedures speciﬁc to a
particular tumor. Furthermore, studies have shown that AuNPs are
promising phototherapeutic agents. Using our imaging technique,
guidance and monitoring of photothermal therapeutic procedures
could also be feasible [32,36,37].
4. Conclusion
We demonstrated that molecular targeted AuNPs and spectro-
scopic photoacoustic imaging has the potential to detect cancer
cells in vivo based on their molecular functionality. In particular,
EGFR-targeted AuNPs underwent molecular-speciﬁc endocytosis
leading to plasmon resonance coupling. The phenomena resulted
in an increase in optical absorption of AuNPs in the NIR region and
hence an increase in the photoacoustic signal. We evaluated
feasibility of photoacoustic imaging in detection of plasmon
resonance coupling of targeted AuNPs in tumors expressing EGFR.
Multi-wavelength photoacoustic images obtained before and after
intravenous injection of EGFR-targeted AuNPs clearly showed a
signiﬁcant increase in red-NIR absorption of the tumor region due
to formation of AuNP aggregates. Furthermore, we demonstrated
3D capabilities of the imaging system in obtaining molecular
signatures of tumor cells.
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